243 related articles for article (PubMed ID: 30078176)
1. A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences.
Maniadakis N; Toth E; Schiff M; Wang X; Nassim M; Szegvari B; Mountian I; Curtis JR
Adv Ther; 2018 Sep; 35(9):1333-1355. PubMed ID: 30078176
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
3. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
Dalén J; Svedbom A; Black CM; Lyu R; Ding Q; Sajjan S; Sazonov V; Kachroo S
Rheumatol Int; 2016 Jul; 36(7):987-95. PubMed ID: 26780533
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations.
Accortt NA; Chung JB; Bonafede M; Limone BL; Mannino DM
Int J Chron Obstruct Pulmon Dis; 2017; 12():2085-2094. PubMed ID: 28790811
[TBL] [Abstract][Full Text] [Related]
5. Biologics in Inflammatory Immune-mediated Systemic Diseases.
Moroncini G; Calogera G; Benfaremo D; Gabrielli A
Curr Pharm Biotechnol; 2017; 18(12):1008-1016. PubMed ID: 29278213
[TBL] [Abstract][Full Text] [Related]
6. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
[TBL] [Abstract][Full Text] [Related]
7. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.
Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ
Clin Rheumatol; 2017 Apr; 36(4):895-901. PubMed ID: 28271234
[TBL] [Abstract][Full Text] [Related]
8. Gender differences in biologic treatment outcomes-a study of 1750 patients with psoriatic arthritis using Danish Health Care Registers.
Højgaard P; Ballegaard C; Cordtz R; Zobbe K; Clausen M; Glintborg B; Kristensen LE; Dreyer L
Rheumatology (Oxford); 2018 Sep; 57(9):1651-1660. PubMed ID: 29893926
[TBL] [Abstract][Full Text] [Related]
9. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.
Bechman K; Oke A; Yates M; Norton S; Dennison E; Cope AP; Galloway JB
Rheumatology (Oxford); 2020 Sep; 59(9):2563-2571. PubMed ID: 31998962
[TBL] [Abstract][Full Text] [Related]
10. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.
Vilarrasa E; Notario J; Bordas X; López-Ferrer A; Gich IJ; Puig L
J Am Acad Dermatol; 2016 Jun; 74(6):1066-72. PubMed ID: 27004803
[TBL] [Abstract][Full Text] [Related]
11. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
Jung YS; Han M; Park S; Cheon JH
Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
[TBL] [Abstract][Full Text] [Related]
12. Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors.
Campanati A; Molinelli E; Brisigotti V; Offidani A
Curr Pharm Biotechnol; 2017; 18(12):945-963. PubMed ID: 29424306
[TBL] [Abstract][Full Text] [Related]
13. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
[TBL] [Abstract][Full Text] [Related]
14. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
Wei W; Knapp K; Wang L; Chen CI; Craig GL; Ferguson K; Schwartzman S
Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study.
Alvarez-Madrazo S; Kavanagh K; Siebert S; Semple Y; Godman B; Maciel Almeida A; Acurcio FA; Bennie M
BMJ Open; 2019 Sep; 9(9):e027059. PubMed ID: 31488467
[TBL] [Abstract][Full Text] [Related]
16. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
[TBL] [Abstract][Full Text] [Related]
17. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
18. Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors.
Dalén J; Svedbom A; Black CM; Kachroo S
Rheumatol Int; 2017 Dec; 37(12):2049-2058. PubMed ID: 28975392
[TBL] [Abstract][Full Text] [Related]
19. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
20. Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data.
Pappas DA; Litman HJ; Lesperance T; Kricorian G; Karis E; Rebello S; Hua W; Accortt NA; Stryker S
Rheumatol Int; 2021 Feb; 41(2):381-390. PubMed ID: 32876744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
